<div id="readability-page-1"><p>Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Monday . The company traded as high as $265.92 and last traded at $253.68, with a volume of 180498 shares traded. The stock had previously closed at $252.17.</p><div><p><span></span><span>Get <strong>Krystal Biotech</strong> alerts:</span></p></div><h2>Wall Street Analysts Forecast Growth</h2><ul><li>Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore</li></ul><p>KRYS has been the topic of a number of analyst reports. HC Wainwright  reissued a &#34;buy&#34; rating and set a $240.00 price target on shares of Krystal Biotech in a research report on Monday, September 15th. Citigroup raised their price target on Krystal Biotech from $166.00 to $198.00 and gave the stock a &#34;neutral&#34; rating in a research report on Tuesday, November 4th. Weiss Ratings  reaffirmed a &#34;hold (c+)&#34; rating on shares of Krystal Biotech in a research report on Monday, December 22nd. Bank of America raised their target price on shares of Krystal Biotech from $182.00 to $255.00 and gave the company a &#34;buy&#34; rating in a report on Friday, October 17th. Finally, Chardan Capital upped their price target on shares of Krystal Biotech from $216.00 to $220.00 and gave the stock a &#34;buy&#34; rating in a report on Tuesday, November 4th. Six investment analysts have rated the stock with a Buy rating and two have assigned  a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock  has an average rating of &#34;Moderate Buy&#34; and an average price target of $228.14.</p><p><b>Get Our Latest Stock Report on KRYS</b></p><h2>Krystal Biotech Price Performance</h2><ul><li>Krystal Clear: Krystal Biotech Clears Resistance in Good Volume</li></ul><p>The company has a market capitalization of $7.36 billion, a price-to-earnings ratio of 38.03 and a beta of 0.48. The firm's fifty day moving average price is $215.65 and its 200-day moving average price is $174.95. </p><p>Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings data on Monday, November 3rd. The company reported $2.66 earnings per share for the quarter, topping analysts' consensus estimates of $1.12 by $1.54. The business had revenue of $97.80 million for the quarter, compared to analyst estimates of $93.72 million. Krystal Biotech had a return on equity of 19.36% and a net margin of 53.30%. On average, research analysts predict that  Krystal Biotech, Inc. will post 6.14 earnings per share for the current year. </p><h2>Insider Buying and Selling at Krystal Biotech</h2><p>In related news, insider Suma Krishnan sold 25,000 shares of the company's stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $220.16, for a total transaction of $5,504,000.00. Following the sale, the insider owned 1,413,711 shares in the company, valued at $311,242,613.76. This represents a 1.74% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at the SEC website. Company insiders own  13.70% of the company's stock. </p><h2>Hedge Funds Weigh In On Krystal Biotech</h2><p>Institutional investors and hedge funds have recently modified their holdings of the business. Soleus Capital Management L.P. increased its stake in shares of  Krystal Biotech by 108.9% in the 2nd quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company's stock valued at $126,870,000 after acquiring an additional 481,200 shares in the last quarter.  UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of  Krystal Biotech by 173.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 575,506 shares of the company's stock valued at $103,764,000 after purchasing an additional 365,304 shares during the period.  Braidwell LP boosted its position in shares of  Krystal Biotech by 81.6% during the 2nd quarter. Braidwell LP now owns 727,811 shares of the company's stock worth $100,045,000 after purchasing an additional 327,067 shares in the last quarter.  Norges Bank acquired a new stake in shares of  Krystal Biotech in the 2nd quarter valued at about $38,861,000.  Finally, First Trust Advisors LP increased its position in  Krystal Biotech by 571.3% in the 2nd quarter. First Trust Advisors LP now owns 222,370 shares of the company's stock valued at $30,567,000 after buying an additional 189,245 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors. </p><h2>Krystal Biotech Company Profile</h2> (Get Free Report)<p>Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.  </p><p>The company's lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.</p><h2>Read More</h2><ul><li>Five stocks we like better than Krystal Biotech</li><li>Do not delete, read immediately</li><li>How the Rich Retire</li><li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li><li>How Long Will $1M Last in Retirement?</li><li>[No Brainer Gold Play]: “Show me a better investment.”</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Krystal Biotech Right Now?</h2><p>Before you consider Krystal Biotech, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Krystal Biotech wasn't on the list.</p><p>While Krystal Biotech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

KRYS

<p>Krystal Biotech (NASDAQ:KRYS) reached a new 52-week high of $265.92 during trading, closing at $253.68. Analysts have given the stock a "Moderate Buy" rating, with an average price target of $228.14. The company reported earnings of $2.66 per share, exceeding estimates, and had a revenue of $97.80 million. Insider trading saw Suma Krishnan sell 25,000 shares, while institutional investors increased their stakes significantly. Krystal Biotech focuses on gene therapies for rare dermatological diseases, utilizing proprietary viral vector technology.</p>

Krystal Biotech (NASDAQ:KRYS) Sets New 52-Week High - What's Next?